CA2342341A1 - A new composition - Google Patents

A new composition Download PDF

Info

Publication number
CA2342341A1
CA2342341A1 CA002342341A CA2342341A CA2342341A1 CA 2342341 A1 CA2342341 A1 CA 2342341A1 CA 002342341 A CA002342341 A CA 002342341A CA 2342341 A CA2342341 A CA 2342341A CA 2342341 A1 CA2342341 A1 CA 2342341A1
Authority
CA
Canada
Prior art keywords
treatment
component
pharmaceutical formulation
composition
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002342341A
Other languages
English (en)
French (fr)
Inventor
Seth-Olov Thorberg
John Evenden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2342341A1 publication Critical patent/CA2342341A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
CA002342341A 1998-09-16 1999-09-13 A new composition Abandoned CA2342341A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9803156A SE9803156D0 (sv) 1998-09-16 1998-09-16 A new composition
SE9803156-0 1998-09-16
PCT/SE1999/001597 WO2000015218A1 (en) 1998-09-16 1999-09-13 A new composition

Publications (1)

Publication Number Publication Date
CA2342341A1 true CA2342341A1 (en) 2000-03-23

Family

ID=20412627

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002342341A Abandoned CA2342341A1 (en) 1998-09-16 1999-09-13 A new composition

Country Status (21)

Country Link
EP (1) EP1128825A1 (xx)
JP (1) JP2002524508A (xx)
KR (1) KR20010099647A (xx)
CN (1) CN1317964A (xx)
AR (1) AR021808A1 (xx)
AU (1) AU6378099A (xx)
BR (1) BR9913748A (xx)
CA (1) CA2342341A1 (xx)
CZ (1) CZ2001961A3 (xx)
EE (1) EE200100157A (xx)
HU (1) HUP0103544A3 (xx)
ID (1) ID28785A (xx)
IL (1) IL141519A0 (xx)
IS (1) IS5879A (xx)
NO (1) NO20011312L (xx)
PL (1) PL346763A1 (xx)
SE (1) SE9803156D0 (xx)
SK (1) SK3262001A3 (xx)
TR (1) TR200100779T2 (xx)
WO (1) WO2000015218A1 (xx)
ZA (1) ZA200101946B (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2269467T3 (es) 2000-10-13 2007-04-01 Neurosearch A/S Tratamiento de transtornos afectivos por la accion combinada de un agonista del receptor nicotinico y una sustancia monoaminergenica.
WO2006093192A1 (ja) * 2005-03-04 2006-09-08 Tokyo Medical And Dental University 覚醒剤精神病及び統合失調症の再発防止治療薬

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination

Also Published As

Publication number Publication date
EE200100157A (et) 2002-08-15
HUP0103544A2 (hu) 2002-05-29
PL346763A1 (en) 2002-02-25
SK3262001A3 (en) 2001-08-06
JP2002524508A (ja) 2002-08-06
EP1128825A1 (en) 2001-09-05
BR9913748A (pt) 2001-07-10
CN1317964A (zh) 2001-10-17
AU6378099A (en) 2000-04-03
TR200100779T2 (tr) 2001-10-22
IL141519A0 (en) 2002-03-10
NO20011312L (no) 2001-05-16
KR20010099647A (ko) 2001-11-09
IS5879A (is) 2001-03-07
ID28785A (id) 2001-07-05
HUP0103544A3 (en) 2003-12-29
AR021808A1 (es) 2002-08-07
NO20011312D0 (no) 2001-03-15
SE9803156D0 (sv) 1998-09-16
CZ2001961A3 (cs) 2001-08-15
ZA200101946B (en) 2002-06-10
WO2000015218A1 (en) 2000-03-23

Similar Documents

Publication Publication Date Title
US6169098B1 (en) Composition and methods employing it for the treatment of 5-HT-mediated disorders
CN103547260B (zh) 用于治疗中枢系统疾病的包含Brexpiprazole或其盐和第二种药物的组合
US20110136865A1 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050203130A1 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JP4571485B2 (ja) D4および5−ht2aアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
EP3400940B1 (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium
US6472423B1 (en) Pharmaceutical composition
CA2342341A1 (en) A new composition
AU6378199A (en) A new composition
CA2342233A1 (en) A new composition
CA2342223A1 (en) A new composition
JP4571645B2 (ja) D4および5−ht2aアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
MXPA01002370A (en) A new composition
MXPA01002543A (en) A new composition
CA2351674A1 (en) Use of a 5ht2a and 5ht2a/c receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways
AU2004269857A1 (en) The combination of a serotonin reuptake inhibitor and Amoxapine

Legal Events

Date Code Title Description
FZDE Discontinued